64 related articles for article (PubMed ID: 38756630)
1. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma.
Song S; Liu Y; Ren Y; Zheng C; Liang B
Diagn Interv Radiol; 2024 Jun; ():. PubMed ID: 38836437
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.
Giraud EL; Westerdijk K; van der Kleij MBA; Guchelaar NAD; Meertens M; Bleckman RF; Rieborn A; Mohammadi M; Roets E; Mathijssen RHJ; Huitema ADR; Koolen SLW; Gelderblom H; Moes DJAR; Reyners AKL; Touw DJ; Keizer-Heldens P; Oosten AW; van der Graaf WTA; Steeghs N; van Erp NP; Desar IME;
ESMO Open; 2024 Jun; 9(6):103477. PubMed ID: 38833964
[TBL] [Abstract][Full Text] [Related]
4. Effect of Chinese Medicine in Patients with COVID-19: A Multi-center Retrospective Cohort Study.
Zhao GZ; Yan SY; Li B; Guo YH; Song S; Hu YH; Guo SQ; Hu J; Du Y; Lu HT; Ye HR; Ren ZY; Zhu LF; Xu XL; Su R; Liu QQ
Chin J Integr Med; 2024 May; ():. PubMed ID: 38816638
[TBL] [Abstract][Full Text] [Related]
5. Gender differences in lung neuroendocrine tumors: a single-center experience.
Liccardi A; Colao A; Modica R
Neuroendocrinology; 2024 May; ():. PubMed ID: 38781933
[TBL] [Abstract][Full Text] [Related]
6. Estimation of treatment policies based on functional predictors.
McKeague IW; Qian M
Stat Sin; 2014 Jul; 24(3):1461-1485. PubMed ID: 25165416
[TBL] [Abstract][Full Text] [Related]
7. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.
Zhu L; Ye X; She Y; Liu W; Hasegawa K; Rossi RE; Du Q; Zhai Q
J Gastrointest Oncol; 2024 Apr; 15(2):689-709. PubMed ID: 38756630
[TBL] [Abstract][Full Text] [Related]
8. Thymic neuroendocrine neoplasms-what we know, what we don't know, and what to do about it.
Lang M; Pausch TM; Anamaterou C
Transl Cancer Res; 2023 Jan; 12(1):1-3. PubMed ID: 36760379
[No Abstract] [Full Text] [Related]
9. Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective.
Ma X; Ding Y; Li W; Li Q; Yang H
Front Oncol; 2022; 12():1061065. PubMed ID: 36483036
[TBL] [Abstract][Full Text] [Related]
10. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE).
Schmidt M; Lübbe K; Decker T; Thill M; Bauer L; Müller V; Link T; Furlanetto J; Reinisch M; Mundhenke C; Hoffmann O; Zahn MO; Müller L; Denkert C; van Mackelenbergh M; Fasching PA; Burchardi N; Nekljudova V; Loibl S
ESMO Open; 2022 Dec; 7(6):100601. PubMed ID: 36356410
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.
Lauricella E; Mandriani B; Cavallo F; Pezzicoli G; Chaoul N; Porta C; Cives M
Front Oncol; 2022; 12():957068. PubMed ID: 36059642
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
Kurita Y; Kobayashi N; Hara K; Mizuno N; Kuwahara T; Okuno N; Haba S; Tokuhisa M; Hasegawa S; Sato T; Hosono K; Kato S; Kessoku T; Endo I; Shimizu Y; Kubota K; Nakajima A; Ichikawa Y; Niwa Y
Intern Med; 2023 Jan; 62(2):159-167. PubMed ID: 35705270
[TBL] [Abstract][Full Text] [Related]
13. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.
Cao Y; Lu M; Sun Y; Gong J; Li J; Lu Z; Li J; Zhang X; Li Y; Peng Z; Zhou J; Wang X; Shen L
J Cancer Res Clin Oncol; 2023 Feb; 149(2):779-789. PubMed ID: 35166929
[TBL] [Abstract][Full Text] [Related]
14. Mixed neuroendocrine nonneuroendocrine neoplasms of the pancreas: a case report and literature review of pancreatic mixed neuroendocrine nonneuroendocrine neoplasm.
Wang F; Lou X; Qin Y; Xu X; Yu X; Huang D; Ji S
Gland Surg; 2021 Dec; 10(12):3443-3452. PubMed ID: 35070904
[TBL] [Abstract][Full Text] [Related]
15. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience.
Touloupas C; Faron M; Hadoux J; Deschamps F; Roux C; Ronot M; Yevich S; Joskin J; Gelli M; Barbé R; Lamartina L; Tissot H; Scoazec JY; Malka D; Ducreux M; Baudin E; de Baère T; Tselikas L
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771531
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Shah MH; Goldner WS; Benson AB; Bergsland E; Blaszkowsky LS; Brock P; Chan J; Das S; Dickson PV; Fanta P; Giordano T; Halfdanarson TR; Halperin D; He J; Heaney A; Heslin MJ; Kandeel F; Kardan A; Khan SA; Kuvshinoff BW; Lieu C; Miller K; Pillarisetty VG; Reidy D; Salgado SA; Shaheen S; Soares HP; Soulen MC; Strosberg JR; Sussman CR; Trikalinos NA; Uboha NA; Vijayvergia N; Wong T; Lynn B; Hochstetler C
J Natl Compr Canc Netw; 2021 Jul; 19(7):839-868. PubMed ID: 34340212
[TBL] [Abstract][Full Text] [Related]
17. [The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)].
Wu WM; Chen J; Bai CM; Chi Y; Du YQ; Feng ST; Huo L; Jiang YX; Li JN; Lou WH; Luo J; Shao CH; Shen L; Wang F; Wang LW; Wang O; Wang Y; Wu HW; Xing XP; Xu JM; Xue HD; Xue L; Yang Y; Yu XJ; Yuan CH; Zhao H; Zhu XZ; Zhao YP;
Zhonghua Wai Ke Za Zhi; 2021 Jun; 59(6):401-421. PubMed ID: 34102722
[TBL] [Abstract][Full Text] [Related]
18. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
Rodriguez-Freixinos V; Thawer A; Capdevila J; Ferone D; Singh S
Curr Oncol Rep; 2021 May; 23(7):80. PubMed ID: 33937962
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
